ArticleEuropean journal of breast health2025
It Is Not an Obituary of Sentinel Lymph Node Biopsy or Surgery to Axilla, It's a De-Escalation of Surgery to Axilla in Early Breast Cancer: A Traditional Review.
Article in European journal of breast health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Axillary De-Escalation: Precision Matters.European journal of breast health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In breast cancer (BC), surgical treatment of the axilla has undergone a paradigm shift from axillary lymph node dissection (ALND), through sentinel lymph node biopsy (SLNB), and ultimately to omission of axillary surgery. In BC, following neoadjuvant systemic therapy (NAST), there has also been a de-escalation from ALND to SLNB and targeted axillary dissection, with false-negative rates reduced to an acceptable level of less than 10%. Trials are ongoing to omit ALND when SLNB is positive in post-NAST BC cases. Additionally, ongoing trials are evaluating the omission of axillary surgery in post-NAST ycN0 patients. Based on an extensive literature search, this review highlights the sequential de-escalation of axillary surgery in patients with early breast cancer (EBC), irrespective of whether surgery was performed upfront or after NAST, with the same oncological outcomes on follow-up. cTis, 1-3 cN0 and cTis, 1-2 cN0-1 EBC patients have been included. Trials and studies involving cT0-4 and cN1-2 BC patients, and trials including both EBC and locally advanced BC patients, have been excluded to keep the study population uniform, consisting only of EBC cases. Examples of trials discussed in this review include NSABP-B04, NSABP-B 32, ACOSOG Z 11, IBCSG 23-01, AMAROS, SENOMAC, SOUND, INT 09/98, ALLIANCE A011202, AXSANA, EUBREAST-01, among others. In conclusion, de-escalation of surgical intervention to the axilla in EBC patients planned for upfront surgery or NAST requires an individualized approach based on the patient's condition and favorable tumor subtype. To date, a positive SLNB after NAST mandates ALND. Trials to nullify the same, with non-inferior oncological outcomes, are underway. There is a shift towards avoiding axillary surgery altogether in favourable BC cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.